German biotech CatalYm raises $150M to repurpose obesity target for cancer

Ayisha Sharma

News Reporter

CatalYm has racked up $150 million in an oversubscribed Series D to advance its antibody drug that neutralizes GDF15 — a target previously explored by other …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

German biotech CatalYm raises $150M to repurpose obesity target for cancer

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Ger­man biotech CatalYm rais­es $150M to re­pur­pose obe­si­ty tar­get for can­cer

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

German biotech CatalYm raises $150M to repurpose obesity target for cancer